Differential contribution of dopamine D2S and D2L receptors in the modulation of glutamate and GABA transmission in the striatum

Diego Centonze, Paolo Gubellini, Alessandro Usiello, Silvia Rossi, Anne Tscherter, Enrico Bracci, Eric Erbs, Nadia Tognazzi, Giorgio Bernardi, A. Pisani, Peter A. Calabresi, Emiliana BorrelliNeuroscience 2004 · DOI

TL;DR

This study reveals that the two main forms of the dopamine D2 receptor (D2S and D2L) play distinct roles in modulating glutamate and GABA signaling in the striatum. While both isoforms contribute to inhibiting GABA transmission, the D2S isoform appears to be the primary driver of dopamine's inhibitory effect on glutamate release, offering crucial insights for understanding and treating neurological disorders linked to dopamine dysfunction.

What Problem Does This Paper Address?

The striatum, a key component of the basal ganglia, is central to motor control, cognition, and emotion. Dopamine (DA) is a critical neuromodulator in this region, influencing both excitatory (glutamate) and inhibitory (GABA) neurotransmission. The dopamine D2 receptor (D2R) is known to mediate these effects, primarily through presynaptic inhibition of neurotransmitter release. However, the D2 receptor gene produces two distinct isoforms, D2S and D2L, through alternative splicing. These isoforms differ in their intracellular loops and are thought to have separate physiological functions. The critical question this paper addresses is: how do these two D2 receptor isoforms differentially contribute to dopamine's modulation of glutamate and GABA transmission in the striatum? Understanding this distinction is vital for developing targeted therapies for conditions like Parkinson's disease, schizophrenia, and addiction, where dopamine signaling is disrupted.

Methods

The researchers employed a sophisticated combination of genetic manipulation and electrophysiology in mice.

  • Genetically Modified Mice: They utilized three types of mutant mice:
  • D2R-/- mice: Lacking both D2S and D2L receptors.
  • D2L-/- mice: Lacking the D2L isoform, leading to an overexpression of the D2S isoform.
  • D2R-/-;D2L-/- mice: A double knockout, used to create a specific genetic background for studying D2S effects.
  • Wild-type (WT) mice: Serving as controls.
  • Electrophysiology: Whole-cell patch-clamp recordings were performed on striatal spiny neurons in acute brain slices. This allowed them to measure:
  • Spontaneous Excitatory Postsynaptic Currents (EPSCs): To assess glutamate release.
  • Spontaneous Inhibitory Postsynaptic Currents (IPSCs): To assess GABA release. Recordings were made in the presence of specific antagonists to isolate glutamatergic and GABAergic currents.

  • Pharmacological Manipulation: The D2 receptor agonist quinpirole was applied to assess the functional impact of D2 receptor activation on synaptic transmission in the different genetic models.

  • Binding Assays: Scatchard analysis was used to quantify the density of D2 receptor binding sites in the striatal membranes of the different mouse lines.

Datasets

Not discussed in the paper. The study relies on electrophysiological recordings from genetically modified and wild-type mice, not on pre-existing datasets.

Key Insights and Ideas

  • Isoform Specialization: The core insight is that D2S and D2L receptors are not functionally redundant. They have distinct roles in modulating striatal neurotransmission.
  • GABA Inhibition: A Shared Responsibility: Both D2S and D2L receptors appear to contribute to dopamine's inhibitory effect on GABA release. This suggests a degree of functional compensation; if one isoform is missing, the other can partially take over.
  • Glutamate Inhibition: D2S Dominance: The D2S isoform is the primary mediator of dopamine's inhibitory effect on glutamate release. This is a significant finding, as it pinpoints a specific isoform responsible for a key aspect of dopamine's influence on excitatory signaling.
  • Overexpression Matters: In D2L-/- mice, where D2S receptors are overexpressed, the inhibitory effect of quinpirole on glutamate release was significantly enhanced. This highlights the impact of receptor density and isoform balance.
  • D2S as a Somatodendritic Autoreceptor: The paper notes that D2S has also been implicated as a somatodendritic autoreceptor in dopaminergic neurons, further underscoring its critical role in basal ganglia function.

Key Results

  • GABAergic IPSCs: Quinpirole (a D2 agonist) significantly reduced spontaneous GABAergic IPSC frequency in WT mice. This effect was lost in D2R-/- mice (no D2 receptors) but preserved in D2L-/- mice (overexpressing D2S). In D2R-/-;D2L-/- mice, the effect was present but reduced, suggesting both isoforms contribute.
  • Glutamatergic EPSCs: Quinpirole did not significantly affect spontaneous EPSC frequency in WT or D2R-/- mice. However, in D2L-/- mice (overexpressing D2S), quinpirole did significantly inhibit EPSC frequency. This effect was lost when D2S levels were normalized in D2R-/-;D2L-/- mice.
  • Basal EPSC Frequency: D2R-/- mice (lacking all D2 receptors) showed a higher frequency of spontaneous EPSPs compared to WT, consistent with a loss of presynaptic D2-mediated inhibition of glutamate release. This effect was absent in D2L-/- mice, further supporting the role of D2S.

Limitations and Future Work

  • Pharmacological Tools: The authors acknowledge that the lack of selective pharmacological tools to distinguish between D2S and D2L isoforms makes it challenging to study their functions independently. This study's reliance on genetic models was crucial due to this limitation.
  • In Vivo vs. In Vitro: While the study provides strong in vitro evidence, future work could explore these isoform-specific roles in vivo to confirm their physiological relevance in behaving animals.
  • Other Dopamine Receptors: The study focuses on D2 receptors. Future research could investigate how D2S and D2L isoforms interact with other dopamine receptor subtypes (D1, D3, D4, D5) and other neurotransmitter systems to orchestrate complex striatal functions.
  • Therapeutic Implications: The findings pave the way for developing more targeted drugs that can selectively modulate D2S or D2L receptor activity, potentially leading to more effective treatments for neurological and psychiatric disorders with fewer side effects.

Summary updated

BibTeX
@inproceedings{centonze2004differential,
  author = {Diego Centonze and Paolo Gubellini and Alessandro Usiello and Silvia Rossi and Anne Tscherter and Enrico Bracci and Eric Erbs and Nadia Tognazzi and Giorgio Bernardi and A. Pisani and Peter A. Calabresi and Emiliana Borrelli},
  title = {{Differential contribution of dopamine D2S and D2L receptors in the modulation of glutamate and GABA transmission in the striatum}},
  booktitle = {Neuroscience},
  year = {2004},
  doi = {10.1016/j.neuroscience.2004.07.043},
}
Figure